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ABSTRACT
Objective: To develop a preoperative nomogram to predict pathologic outcome in patients submitted to radical prostatectomy
for clinical localized prostate cancer.
Materials and Methods: Nine hundred and sixty patients with clinical stage T1 and T2 prostate cancer were evaluated
following radical prostatectomy, and 898 were included in the study. Following a multivariate analysis, nomograms were
developed incorporating serum PSA, biopsy Gleason score, and percentage of positive biopsy cores in order to predict the
risks of extraprostatic tumor extension, and seminal vesicle involvement.
Results: In univariate analysis there was a significant association between percentage of positive biopsy cores (p < 0.001),
serum PSA (p = 0.001) and biopsy Gleason score (p < 0.001) with extraprostatic tumor extension. A similar pathologic
outcome was seen among tumors with Gleason score 7, and Gleason score 8 to 10. In multivariate analysis, the 3 preoperative
variables showed independent significance to predict tumor extension. This allowed the development of nomogram-1
(using Gleason scores in 3 categories - 2 to 6, 7 and 8 to 10) and nomogram-2 (using Gleason scores in 2 categories - 2 to
6 and 7 to 10) to predict disease extension based on these 3 parameters. In the validation analysis, 87% and 91.1% of the
time the nomograms-1 and 2, correctly predicted the probability of a pathological stage to within 10% respectively.
Conclusion: Incorporating percent of positive biopsy cores to a nomogram that includes preoperative serum PSA and
biopsy Gleason score, can accurately predict the presence of extraprostatic disease extension in patients with clinical
localized prostate cancer.
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INTRODUCTION
Gleason grade from biopsy, along with serum
PSA and tumor extent at digital rectal examination,
are the current most common parameters used to
predict the risk of organ confined disease and choose
a definitive treatment in patients with prostate cancer
(1).
However, some studies show that clinical
stage as defined at digital rectal examination is neither
the ideal method to choose a definitive therapy (2)
nor to predict biochemical outcome after treatment
(3-6). The percentage of patients staged as T1c
increased from less than 1% in the eighties to 60% in
the nineties. Furthermore, a study of more than 1000
patients that underwent radical retropubic
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prostatectomy did not find statistical difference in
disease recurrence rates among patients staged as T2a,
T2b or T2c at digital rectal examination after a 10
years follow up period (7).
New variables to predict the probabilities of
organ confined disease and disease recurrence after
treatment have been widely studied (8-10), and the
percentage of positive biopsy cores (PPBC) for
cancer has emerged as an independent prognostic
factor (11-13). Probably, the reason for this
importance is based on its straight relation with
tumor volume in radical prostatectomy specimens
(14).
As discussed above, several individual
parameters have the power to preoperatively predict
the risk of the actual pathologic stage and biochemical
outcome after treatment. For this reason, many authors
have analyzed the use of pre- and postoperative
nomograms in order to find patients in which a high
risk of extra-prostatic disease (15) or high rates of
disease progression are expected (16,17).
The first nomogram developed by Partin et
al. (18), to predict the risks of nomogram confined
disease and involvement of seminal vesicles and iliac
lymph nodes in patients that underwent radical
retropubic prostatectomy, included the biopsy Gleason
score, clinical stage and serum PSA levels.
Considering that the percent positive biopsy
cores represent an important prognostic factor (19),
clinical stage as defined at digital rectal examination
is not as relevant as it was thought before (4) and
some studies incorporated the PPBC into models of
prognostic value (8), in the present study we analyzed
the predictive power of a new nomogram including
the preoperative serum PSA and the biopsy Gleason
score along with the PPBC.
MATERIALS AND METHODS
Between September 1988 and December
2002, 960 patients with clinically localized prostate
cancer who underwent radical retropubic
prostatectomy were retrospectively studied. All the
patients underwent clinical and pathological staging
according to the TNM staging system (20).
From the 960 patients, only those men with
complete information regarding the total number of
biopsy cores, number of fragments with cancer, biopsy
Gleason score, serum PSA levels and pathologic
analysis of the surgical specimen were studied. Fifty-
four patients that received neoadjuvant androgen
deprivation therapy or were diagnosed through
transurethral resection or transvesical prostatectomy
were excluded. A total of 898 remained in study.
Table-1 shows the patients characteristics.
The same surgeon (MS) performed all the
surgical procedures according to the Walsh technique
(21), modified by Srougi (22). The same pathologist
(KRL) analyzed all the surgical specimens, includ-
ing the prostate gland, seminal vesicles and obturatory
lymph.
Macroscopic Analysis
The specimens of radical prostatectomy were
fixed in buffered formalin 10% for a period of 6h.
After weighting and measuring the gland, thin
transversal sections were performed in the surgical
margins related to the bladder neck and the prostate
apex. The seminal vesicles were sectioned in the base
and longitudinal sections were submitted to
histological examination. The entire gland was
included for study after having their margins painted
with India ink. The right and left lobes were separated,
with sequential transversal sections being performed
every 3 mm, designed from the proximal region
towards the distal one. Between 10 and 12 sections
from each lobe were included for histological study.
The lymph nodes from the fat related to the resection
of the iliac chain were dissected and sections
representative of each nodular structure were included
for study.
Microscopic Analysis
The specimens underwent the usual
processing with inclusion in paraffin. Sections of 4
to 6 mm were stained by hematoxylin-eosin. The
analyzed parameters were:
Histological pattern and Gleason score - The
Gleason histological grade was used for evaluating
the histological differentiation, considering only the
acinar pattern (23).
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Table 1  –  Demographic and clinical features of the 898
patients.
N Patients 898
Age (years)
Mean ± SD 062.9 ± 7.4
Median 063.5
Minimum – maximum 040 - 83
PSA (ng/mL)
Mean ± SD 010.1 ± 7.3
Median 008.0
Minimum – Maximum 000.3 - 63.5
0 to 4.0 084 0(9.4%)
4.1 to 10.0 512 (57.0%)
10.1 to 20.0 236 (26.3%)
> 20.0 066 (7.3%)
Gleason
2 to 6 653 (72.7%)
7 165 (18.4%)
8 to 10 080 (8.9%)
Clinical Stage
T1c 432 (48.1%)
T2 459 (51.1%)
T3a 007 (0.8%)
Pathologic Stage
T2 599 (66.7%)
T3 296 (33.0%)
T4 003 (0.3%)
Total Number of Cores
Mean ± SD 008.1 ± 3.3
Median 007.0
Minimum – maximum 002.0 - 22.0
Number of Positive Cores
Mean ± SD 003.2 ± 2.1
Median 003.0
Minimum – maximum 001.0 - 20.0
Percent Positive Biopsy Cores
Mean ± SD 041.2% ± 24.1%
Median 033.3%
Minimum – maximum 005.0% - 100.0%
0 to 25.0% 290 (32.3%)
25.1 to 50.0% 392 (43.7%)
50.1 to 75.0% 134 (14.9%)
75.1 to 100.0% 082 (9.1%)
Surgical margins - Positive margin was
defined if carcinoma was within the bladder neck or
distal urethral shave tissues, or if India ink was
identified on tumor cells at a peripheral margin.
Extra-prostatic involvement - The invasion
of adipose tissue and the periprostatic neurovascular
plexus was considered as involvement of extra-
prostatic tissue and, therefore, non organ-confined
disease.
Seminal vesicle involvement - The
involvement of seminal vesicle parenchyma and not
only the adventitial tissue was considered seminal
vesicle involvement.
Lymph node metastasis - The obturatory
lymph nodes involved with cancer were designated
as metastatic lymph nodes, and no difference
regarding micro or macro-metastasis was considered.
To final analysis, the TNM 2002 (20) staging
system was used.
The finding of an organ-confined disease was
compared to the PPBC, serum PSA levels and Gleason
score through a logistic regression model.
A multinomial logistic regression analysis
(24) with 3 answers was performed: organ-confined
disease, extraprostatic extension and seminal vesicle
involvement. The predictive variables were the
serum PSA levels, divided in categories of 0 to 4
ng/mL; 4.1 to 10.0 ng/mL; 10.1 to 20 ng/mL and
greater than 20 ng/mL, the biopsy Gleason score,
divided in categories of 2 to 6; 7 and 8 to 10, and
then analyzed in groups of 2 to 6 and 7 to 10, and
the PPBC, divided in categories of 0 to 25%; 25.1
to 50%; 50.1 to 75%; 75.1 to 100%. PPBC was
defined using the formula, number of positive cores
/ total biopsy cores X 100.
Considering the association of the 3
parameters with disease extension on univariate and
multivariate analysis, nomograms were developed
based on the probabilities predicted by the adjusted
model. A 95% confidence interval for the final model
was obtained by repeating the analysis on 1000
bootstrap samples from the original cohort (25). The
percentage of the bootstrap observed probabilities that
were within 10% of the nomogram value was shown.
Sensitivity, specificity, positive predictive value and
negative predictive value were also determined. A
significance level of 5% was adopted, and therefore,
statistical significance was set as a p ≤ 0.05. Statistical
analysis was performed in the R for Windows
software.
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RESULTS
Table-2 shows that number of cores retrieved
from biopsy and patient age was not related to the
pathologic findings of the surgical specimen.
Conversely, the PPBC, biopsy Gleason score and
initial PSA levels showed relation with disease
extension. According to multivariate analysis, these
three studied variables were independent prognostic
factors for predicting prostate cancer extension
(Table-2).
Table-3 shows a nomogram-1 that allows pre-
diction of organ-confined disease according to pre-
operative PSA levels, biopsy Gleason score and
PPBC. However, nomogram-1 also shows that if we
keep unchanged the PSA and PPBC values, the con-
fidence intervals of patients with Gleason score 7 are
the same of those with Gleason score 8 to 10 regard-
ing the finding of organ-confined disease. This fact
led us to develop a nomogram-2 (Table-4), using
Gleason categories of 2 to 6 and 7 to 10, without los-
ing predictive power and making it more practical
for clinical use.
A validation analysis compared the predicted
probabilities from the nomogram-1 with the observed
probabilities from additional 1000 bootstrap samples
OR 95% CI p Value
N. of cores 0.99 [0.95 - 1.03] < 0.669
Age (years) 1.02 [0.99 - 1.04] < 0.091
Serum PSA < 0.011
4.1-10 versus 0-4.0 1.67 [0.96 - 2.90] < 0.071
10.1-20 versus 0-4.0 2.39 [1.33 - 4.27] < 0.003
> 20.0 versus 0-4.0 2.38 [1.16 - 4.89] < 0.018
Gleason < 0.001
7 / 2-6 3.19 [2.25 - 4.54] < 0.001
8-10 / 2-6 3.01 [1.88 - 4.83] < 0.001
Percentage of  positive cores < 0.001
25.1-50.0 versus 0-25.0 1.48 [1.05 - 2.08] < 0.025
50.1-75 versus 0-25.0 2.02 [1.30 - 3.13] < 0.002
75.1-100 versus 0-25.0 3.94 [2.36 - 6.58] < 0.001
OR  95% CI p Value
PSA < 0.057
4.0-10 versus 0-4.0 1.58 [0.89 - 2.80] < 0.120
10.0-20 versus 0-4.0 2.17 [1.18 - 3.97] < 0.012
> 20.0 versus 0-4.0 1.99 [0.94 - 4.25] < 0.074
Gleason < 0.001
7 / 0-6 2.96 [2.06 - 4.26] < 0.001
8-10 / 2-6 2.86 [1.76 - 4.64] < 0.001
Percentage of positive cores < 0.001
25.0-50.0 versus 0-25.0 1.35 [0.95 - 1.93] < 0.096
50.0-75 versus 0-25.0 1.58 [0.99 - 2.50] < 0.053
75.0-100 versus 0-25.0 3.04 [1.78 - 5.20] < 0.001
      Univariate Analysis
    Multivariate Analysis
Table 2 – Univariate and multivariate analysis for predicting organ-confined disease.
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     PPBC    0 to 4.0 4.1 to 10.0 10.1 to 20.0   > 20.0   0 to 4.0 4.1 to 10.0 10.1 to 20.0   > 20.0
00.0 to 25% 86 (78-92) 80 (75-85) 75 (69-82) 78 (66-87) 70 (57-81) 59 (50-67) 51 (40-62) 54 (37-69)
25.1 to 50% 82 (75-90) 75 (70-80) 69 (63-76) 71 (59-83) 64 (51-77) 51 (43-59) 42 (33-52) 44 (30-60)
50.1 to 75% 80 (68-89) 72 (63-80) 66 (55-75) 68 (53-81) 59 (43-75) 47 (36-58) 39 (27-51) 41 (26-57)
75.1 to 100% 72 (57-84) 59 (47-71) 50 (37-62) 51 (35-67) 47 (29-66) 32 (21-44) 23 (14-33) 23 (12-36)
Table 4 – Nomogram - Prediction of organ-confined disease according to preoperative PSA levels, biopsy Gleason score and percent positive biopsy
cores (PPBC)*.
* Numbers represent percent predictive probability (95% confidence interval).
                   Gleason Score  Gleason Score
                           2 to 6        7 to 10
                    PSA (ng/mL)    PSA (ng/mL)
Table 3 – Nomogram - Prediction of organ-confined disease according to preoperative PSA levels, biopsy Gleason score and percent positive biopsy
cores (PPBC)*
      PPBC  0 to 4.0 4.1 to 10.0     10.1 to 20.0   > 20.0   0 to 4.0 4.1 to 10.0    10.1 to 20.0   > 20.0   0 to 4.0 4.1 to 10.0 10.1 to 20.0   > 20.0
00.0 to 25% 86 (78-93) 80 (75-85) 75 (68-82) 78 (65-87) 69 (55-83) 59 (48-69) 51 (39-63) 53 (35-70) 70 (53-84) 59 (47-71) 52 (38-65)   x
25.1 to 50% 82 (74-90) 75 (69-80) 69 (61-75) 71 (59-82) 63 (50-77) 51 (42-60) 42 (31-52) 43 (28-60) 64 (46-79) 52 (38-64) 43 (30-56) 45 (27-63)
50.1 to 75% 80 (67-90 72 (63-80) 66 (55-76) 68 (53-82) 59 (43-76) 47 (36-59) 39 (27-51) 40 (25-58)  x 48 (33-62) 40 (25-55) 42 (25-61)
75.1 to 100% 72 (55-85) 59 (46-71) 50 (37-63) 51 (34-67) 46 (29-68) 31 (21-44) 22 (13-34) 22 (12-37)  x 33 (20-48) 24 (13-38) 24 (12-42)
      Gleason Score     Gleason Score Gleason Score
              2 to 6               7        8 to 10
        PSA (ng/mL)       PSA (ng/mL) PSA (ng/mL)
* Numbers represent percent predictive probability (95% confidence interval), X = lack of sufficient data to calculate probability.
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from the study group. In the validation study, 87.0%
of the time the nomograms correctly predicted the
probability of a pathological stage to within 10%. The
same was applied to validation of nomogram-2, which
used Gleason score categories of 2 to 6 and 7 to 10.
In this case, the validation study showed that in 91.1%
the time the nomogram correctly predicted the
probability of a pathological stage to within 10%.
Tables-5 and 6 shows the sensitivity, specificity,
positive predictive value, and negative predictive
value achieved for various predicted probability cutoff
values for organ-confined cancer when assessed in
the 1000 validation bootstrap samples.
COMMENTS
After Partin’s pioneer idea of creating
nomograms to predict prostate cancer extension in
1993 (18), several other models using different
variables were developed to predict disease extension
and/or recurrence. However, some of them are not
practical for clinical use due to the complexity of its
interpretation and most present a lack of significant
accuracy due to the relative imprecision of the
prognostic variables utilized.
Our study presents a nomogram to predict
disease extension in patients with clinical localized
prostate cancer on the basis of preoperative serum
PSA, biopsy Gleason score and PPBC as a new
parameter to be included, with more accurate results
than the isolated analysis of each variable separately.
The finding of an organ-confined disease after
radical retropubic prostatectomy varies from 13 to
82% of cases (18,26). In the present study, we found
a 66.7% rate. This variation depends on the biopsy
Gleason score, serum PSA levels and PPBC, however
even with all these variables being favorable, there is
still a chance of 20% of extra-prostatic extension (19).
The development of the present nomogram
was not based on the clinical stage as proposed by
Partin et al. (15), because we believe this variable is
losing clinical significance as more than 60% of
patients with prostate cancer are staged as T1c (27).
This distribution differs from what was observed
during the eighties, where less than 1% of cases were
detected due to serum PSA level elevation (28).
Furthermore, in prostate screening programs, only
10% of patients underwent transrectal needle biopsy
due to abnormalities on digital rectal examination
(29).
Since tumoral volume has emerged as an
important prognostic factor of pathologic findings and
disease recurrence, the PPBC has been used to predict
pathologic (12) and biochemical outcome after
treatment (19,30). This idea gained support after the
demonstration of a linear relationship between PPBC
and tumoral volume at radical prostatectomy
specimen (31).
There is also a relation between the presence
of Gleason patterns 4 or 5 on biopsy and on surgical
specimens, showing that this finding at biopsy
samples has prognostic value for the patient (31). In
fact, 13% of the patients with biopsy Gleason score
less than 7 show disease recurrence while almost 60%
with a Gleason score was 7 to 10 did (32). In our
series, only 48.8% of patients with a Gleason score
between 8 to 10 had an organ-confined disease, while
this finding occurred in 74.1% of patients with scores
under 7. Thus, if we apply the nomogram in a patient
with all favorable variables (PSA less than 4 ng/mL,
less than 25% positive biopsy cores and Gleason score
less than 7), this number reaches 86% of chances of
an organ-confined disease.
When comparing patients with Gleason score
7 to patients with Gleason score 8 to 10, we noted
that when keeping serum PSA values between 4 and
10 ng/mL and positive biopsy cores under 25%, the
probability of finding an organ-confined disease was
60% and 61% respectively. For this reason, we
decided to construct an easier nomogram considering
only categories of 2 to 6 and 7 to 10. This finding
demonstrates that tumors with Gleason score 7 can
present a similar behavior when compared to scores
8 to 10, probably due to the fact that patients with
Gleason score 7 also own different percentages of
patterns 4 or even 5.
Despite all these evidences, there are still
some controversies regarding cases with Gleason
score 7 presenting a different behavior when com-
pared to patients with Gleason scores 8 to 10 (33). As
we know, the Gleason score 7 is composed by the
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Table 5 – Predictive performance (median [95% confidence interval]) of organ-confined disease nomograms in 1000
validation bootstrap samples (nomogram-1).
Probability
≥ 0.10
≥ 0.15
≥ 0.20
≥ 0.25
≥ 0.30
≥ 0.35
≥ 0.40
≥ 0.45
≥ 0.50
≥ 0.55
≥ 0.60
≥ 0.65
≥ 0.70
≥ 0.75
≥ 0.80
≥ 0.85
≥ 0.90
 Sensitivity, %
100.0 (100-100)
100.0 (99.7-100)
100.0 (99.2-100)
099.7 (98.8-100)
099.3 (97.7-100)
098.7 (96.3-99.7)
097.2 (93.5-99.4)
094.8 (88.6-98.1)
090.1 (83.8-95.7)
084.6 (79.2-91.6)
080.3 (75.2-85.8)
076.0 (65.7-81.4)
066.5 (45.3-77.8)
047.6 (23.1-67.6)
021.7 (0-48.5)
003.3 (0-12.8)
000.0 (0-5.2)
 Specificity, %
000.0 (0-0)
000.0 (0-3.7)
001.0 (0-6.1)
003.3 (0-10.1)
005.6 (1.0-12.6)
009.2 (2.8-17.4)
013.6 (6.0-24.5)
020.0 (9.9-35.8)
029.8 (16.1-44.3)
039.9 (25.1-49.4)
045.8 (34.7-53.7)
051.5 (42.1-62.6)
061.8 (49.1-75.8)
076.0 (60.9-89.8)
091.4 (77.4-100)
098.6 (95.9-100)
100.0 (98.2-100)
66.8 (63.7-69.9)
66.9 (63.8-70.0)
67.1 (64.1-70.5)
67.6 (64.5-70.9)
68.0 (64.9-71.3)
68.7 (65.5-71.9)
69.5 (66.4-72.8)
70.7 (67.4-74.0)
72.2 (69.1-75.8)
73.8 (70.4-77.3)
74.9 (71.7-78.1)
75.9 (72.7-79.3)
77.5 (74.2-81.0)
80.2 (76.4-84.6)
83.6 (70.4-90.9)
85.6 (67.9-95.6)
87.0 (72.1-98.1)
100.0 (91.3-100)
100.0 (50.0-100)
088.9 (33.3-100)
083.3 (50.0-100)
080.0 (50.0-100)
076.9 (55.9-92.3)
071.0 (58.6-87.5)
065.3 (56.1-77.3)
060.2 (53.9-68.1)
056.3 (51.0-61.9)
053.5 (47.9-58.7)
051.1 (45.8-56.4)
047.6 (41.7-53.9)
041.6 (36.8-48.7)
036.3 (32.6-40.8)
033.9 (30.5-37.0)
033.3 (30.1-36.4)
Positive Predictive
       Value, %
Negative Predictive
        Value, %
100 (84.0-100)
100 (60.5-100)
88.2 (50.0-100)
80.0 (44.4-100)
80.0 (50.0-100)
77.2 (52.6-94.1)
71.1 (54.3-88.6)
64.9 (54.5-81.1)
59.7 (53.1-67.4)
55.7 (50.3-61.5)
53.1 (47.7-58.1)
50.9 (45.7-56.0)
47.7 (42.4-53.4)
41.7 (36.9-48.7)
36.3 (32.6-41.2)
33.6 (30.8-37.0)
33.2 (30.2-36.3)
Table 6 – Predictive performance (median [95% confidence interval]) of organ-confined disease nomograms in 1000
validation bootstrap samples (nomogram-2).
Probability
≥ 0.10
≥ 0.15
≥ 0.20
≥ 0.25
≥ 0.30
≥ 0.35
≥ 0.40
≥ 0.45
≥ 0.50
≥ 0.55
≥ 0.60
≥ 0.65
≥ 0.70
≥ 0.75
≥ 0.80
≥ 0.85
≥ 0.90
  Sensitivity, %
100.0 (100-100)
100.0 (99.7-100)
100.0 (99.1-100)
099.5 (98.7-100)
099.3 (98.1-100)
098.8 (96.1-99.8)
097.3 (94.0-99.5)
094.8 (88.7-98.8)
090.3 (83.5-95.8)
084.1 (79.0-91.9)
079.9 (74.0-85.1)
075.7 (65.4-80.6)
066.6 (50.7-77.8)
048.5 (26.5-68.0)
023.5 (0-39.7)
003.2 (0-12.1)
000.0 (0-5.0)
  Specificity, %
000.0 (0-0)
000.0 (0-3.4)
000.0 (0-6.1)
003.3 (0-10.7)
005.6 (0-12.4)
009.1 (2.1-18.3)
013.0 (5.2-23.3)
019.4 (8.9-34.5)
028.9 (15.1-44.6)
040.2(24.0-49.8)
046.1 (36.0-54.4)
051.7 (43.5-63.7)
061.4 (49.3-73.1)
075.5 (61.4-89.2)
090.6 (82.5-100)
098.7 (95.7-100)
100.0 (98.2-100)
66.8 (63.9-69.8)
66.9 (63.9-69.8)
67.2 (64.2-70.1)
67.6 (64.6-70.6)
68.1 (65.2-71.1)
68.7 (65.7-71.6)
69.5 (66.5-72.6)
70.5 (67.7-73.8)
72.0 (69.0-75.8)
73.8 (70.5-77.1)
74.9 (71.9-77.9)
76.0 (73.2-79.2)
77.6 (74.6-81.1)
80.2 (76.8-84.6)
83.7 (73.1-92.4)
86.6 (67.4-96.7)
86.7 (69.6-99.2)
Positive Predictive
       Value, %
Negative Predictive
        Value, %
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sum of the two most prevalent glandular patterns that
most frequently can be 3+4 or 4+3. Some studies have
shown that the percentage of Gleason pattern 4 is re-
lated to extension and severity of the disease (31),
motivating comparisons of these two scores. Chan et
al. (34) found an organ-confined disease rate of 34.7%
among patients with surgical Gleason score 7 that
underwent radical prostatectomy. However, the risk
of disease progression after surgery was 20% greater
for patients with Gleason 4+3 when compared to pa-
tients with Gleason score 3+4 after 10 years follow
up. It is important to point out that these results were
based on analysis of the surgical specimens and not
on biopsy samples as we discussed before (33). Con-
versely, Groeber et al. (35) did not find any differ-
ence between the groups with Gleason score 3+4 or
4+3 regarding extra-prostatic extension or seminal
vesicle involvement.
In the present study we ratify the greater ac-
curacy of the nomograms when compared to the analy-
sis of a single prognostic variable. In patients with
serum PSA between 0 to 4 ng/mL, the chance of an
organ-confined disease was 78.6%, however, when
considering biopsy Gleason score and PPBC, we
found that the finding of an organ-confined disease
can be observed in 70 to 86% of cases. Gancarczyk
et al. (8), developed a nomogram based on the same
variables and showed a 72% rate of an organ-con-
fined disease when serum PSA was 4 ng/mL or lower.
However, as shown in our series, when considering
the biopsy Gleason score and PPBC, this rate varied
from 54 to 80%. The same reasoning can be applied
when considering biopsy Gleason score as a single
variable that defines a 74.1% chance of an organ-con-
fined disease in a patient with score 2 to 6. However,
when all these three variables are considered together,
we found that the same patient present a 51 to 86%
chance of an organ confined disease. We also noted
that patients with more than 75% positive biopsy cores
have a 43.9% chance of presenting an organ-confined
disease, the same number found by Gancarczyk et al.
(8) considering a cut point of 60% for positive bi-
opsy cores. However, this probability rises to 71%
with favorable PSA levels and Gleason scores and
reduces to 26% when both variables were unfavor-
able.
Finally, in the present study, we confirmed
the superiority of the nomograms when compared to
the analysis of a single prognostic factor. We
emphasize that the PPBC is a very important
parameter that should be incorporated in preoperative
models, and that patients with biopsy Gleason score
7 can show the same disease extension when
compared to patients with Gleason score 8 to 10.
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